No Data
No Data
No Data
No Data
No Data
Arcus Biosciences to Present New Data From Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancers will be presented in a special ASCO plenary series rapid abstract update session by
BusinesswireApr 24 16:00 ET
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will
BusinesswireApr 23 16:05 ET
Express News | NYSE Order Imbalance 59853.0 Shares on Sell Side 59853.0 Shares on Sell Side
Moomoo 24/7Apr 18 15:50 ET
Express News | NYSE Order Imbalance 61111.0 Shares on Sell Side
Moomoo 24/7Apr 17 15:50 ET
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)
TipRanksApr 12 06:50 ET
Exelixis Slips as Barclays Downgrades on Lack of Catalysts
Seeking AlphaApr 11 10:10 ET
No Data
No Data